1. Home
  2. ENTA vs MATV Comparison

ENTA vs MATV Comparison

Compare ENTA & MATV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Enanta Pharmaceuticals Inc.

ENTA

Enanta Pharmaceuticals Inc.

HOLD

Current Price

$13.71

Market Cap

382.7M

Sector

Health Care

ML Signal

HOLD

Logo Mativ Holdings Inc.

MATV

Mativ Holdings Inc.

HOLD

Current Price

$7.81

Market Cap

440.9M

ML Signal

HOLD

Company Overview

Basic Information
Metric
ENTA
MATV
Founded
1995
1995
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Paper
Sector
Health Care
Basic Materials
Exchange
Nasdaq
Nasdaq
Market Cap
382.7M
440.9M
IPO Year
2012
1996

Fundamental Metrics

Financial Performance
Metric
ENTA
MATV
Price
$13.71
$7.81
Analyst Decision
Strong Buy
Analyst Count
5
0
Target Price
$20.40
N/A
AVG Volume (30 Days)
245.3K
476.9K
Earning Date
05-11-2026
05-06-2026
Dividend Yield
N/A
4.24%
EPS Growth
29.93
N/A
EPS
N/A
N/A
Revenue
$102,814,000.00
N/A
Revenue This Year
$7.76
$2.97
Revenue Next Year
N/A
$4.20
P/E Ratio
N/A
N/A
Revenue Growth
16.48
N/A
52 Week Low
$6.44
$6.17
52 Week High
$17.15
$15.48

Technical Indicators

Market Signals
Indicator
ENTA
MATV
Relative Strength Index (RSI) 50.55 48.68
Support Level $13.19 $7.21
Resistance Level $13.97 $8.32
Average True Range (ATR) 0.80 0.39
MACD -0.02 0.04
Stochastic Oscillator 30.12 62.18

Price Performance

Historical Comparison
ENTA
MATV

About ENTA Enanta Pharmaceuticals Inc.

Enanta Pharmaceuticals Inc is a biotechnology company that uses a chemistry-based drug discovery approach to develop small-molecule candidates for virology and immunology applications. It focuses on Virology and Immunology. Its active development programs in virology are focused on respiratory syncytial virus, or RSV, and SARS-CoV-2, and Hepatitis B virus. In immunology, the company is engaged in designing and developing potent and selective, oral small molecule inhibitors for the treatment of type 2 inflammatory disease. The company has collaborated with AbbVie, which markets its protease inhibitor paritaprevir, with additional inhibitors in development. The company generates the majority revenue in the form of royalty revenue.

About MATV Mativ Holdings Inc.

Mativ Holdings Inc is a leader in specialty materials, solving its customers' complex challenges by engineering bold, inventive solutions that connect, protect, and purify the world. The company operates in two segments, namely Filtration & advanced Materials, focused on filtration media and components, developed films, coating and converting solutions, and extruded mesh products, and (2) Sustainable & Adhesive Solutions (SAS), focused on tapes, labels, liners, specialty paper, packaging, and healthcare solutions.

Share on Social Networks: